Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is intended for individuals who are doing well on HAART therapy. In Step 1 of the trial, individuals will be given up to 6 infusions of the study drug VRX496 to see the effect on viral load and CD4 counts. If individuals have no serious adverse effects from the infusions of VRX496 and the viral load and CD4 counts remain stable, they may go on to Step 2 of the study. In Step 2, individuals will stop taking their HAART medication and their viral load, CD4 counts and the number of VRX496 in T cells will be monitored.

All subjects who receive VRX496 T cells will enroll in a Long-Term Follow-up study to monitor subjects. Subjects will be followed every 6 months for five years following the 1st infusion of the T cells. If the VRX496 T cells are no longer found in the blood after five years, then subjects will be contacted yearly for the next 10 years. If the VRX496 T cells are found in the blood at five years after the 1st infusion of T cells, then the subjects will continue to be seen once a year until the VRX496 T cells are no longer found in the blood for a maximum of 15 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

NCT00131560

HIV Infection

UNKNOWN PHASE2

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

NCT00622232

HIV Infections

UNKNOWN PHASE2

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756

HIV Infections

COMPLETED PHASE1

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227

HIV Infections

COMPLETED PHASE1

Autologous CD4 T-Cells in HIV (C34-CXCR4)

NCT03020524

Hiv

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HIV-based antisense vectors may provide several important advantages over current HIV combination therapies. VIRxSYS Corporation (VIRxSYS) is developing the candidate clinical vector VRX496. VRX496 is an HIV-based lentiviral vector containing an anti-HIV antisense sequence targeted to the HIV envelope (env) coding sequence. First, HIV-1 vectors are likely to be less toxic than current combination drug therapies because the genetic antisense antiviral is expressed only in cells that become infected with wt-HIV. The payload is located upstream of a major splice acceptor site and is thus dependent on the expression of Tat and Rev proteins that are provided by wt-HIV. Second, the length of the antisense region is over 900 nucleotides long, making it difficult for wt-HIV to create resistant strains that are sufficiently fit to cause disease. Third, HIV vectors are predicted to be safe because no novel genetic sequences are introduced into the patient (i.e., no novel functional genes are contained in the HIV-1 vector). All the sequences present in the vector are derived from highly conserved regions of wt-HIV that would almost certainly be present in any HIV-1-infected individual. The HIV sequences that are used to create VRX496 are solely derived from pNL4-3, a prototypic HIV-1 molecular clone that is derived from two North American strains of HIV-1.

In the present trial, T cells will be harvested from infected individuals, transduced ex vivo with the vector at the University of Pennsylvania, and then reintroduced by autologous transfusions. VIRxSYS recently completed a Phase 1 clinical study at the University of Pennsylvania of the vector VRX496 in 5 HIV-positive subjects who had failed at least two HAART regimens. Data available to date for the primary endpoints, viral load and CD4 counts, are promising. Specifically, 4 of 5 subjects had stable or increased CD4 counts, and viral loads were stable in 4 of 5 patients, and decreased by 1.7 log in 1 of 5 subjects following a single infusion of VRX496 T cells. In the present trial, subjects will receive up to 6 infusions of VRX496 modified CD4 T cells, and then undergo a series of tests, including rectal mucosal biopsies, to determine the longevity and trafficking of the VRX496 T cells. In addition, subjects will have the opportunity to have a supervised drug holiday (structured treatment interruption) to determine if the VRX496 have an antiviral effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VRX496

In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 positive by western blot or detection of HIV RNA in blood and responding to combination antiviral therapy
* No changes in antiretroviral medications within past 4 weeks of study entry and willing to continue on current therapy for the duration of the study
* 18 years of age and older
* Karnofsky Performance score of greater than 80
* HIV viral load \< 59 copies/mL
* CD4 T cell count \> 350 cells per uL
* adequate venous access

Exclusion Criteria

* HIV seroconversion within past year
* History of cancer (other than a removed basal or squamous cell of the skin)
* History of congestive heart failure.
* Previous treatment with HIV experimental vaccine within past year
* Previous treatment with any gene therapy
* Positive serology for Vesicular Stomatitis Virus (VSV-G or VSV-G DNA)
* Currently breastfeeding, pregnant, or unwilling to use birth control
* Using oral corticosteroids, hydroxyurea, or immunomodulating agents (IL-2, interferon-gamma, granulocyte colony stimulating factors, megestrol acetate) within the past 30 days or foresee the need to use these during the study period.
* Are presently drug or alcohol dependent
* Have other serious illness or acute opportunistic infection or bacterial infection requiring systemic treatment and/or hospitalization within the past 30 days
* Have chronic hepatitis B or hepatitis C
* Have an active AIDS defining illness
* Have an allergy or hypersensitivity to human serum albumin, DMSO or Dextran 40
* Have diabetes or a coagulopathy with in the opinion of the investigator would exclude subjects from participating in rectal biopsy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No